111In-LLP2A-DOTA Polyethylene Glycol-Targeting {alpha}4{beta}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.

@article{Denardo2009111InLLP2ADOTAPG,
  title={111In-LLP2A-DOTA Polyethylene Glycol-Targeting \{alpha\}4\{beta\}1 Integrin: Comparative Pharmacokinetics for Imaging and Therapy of Lymphoid Malignancies.},
  author={Sally J. Denardo and Ruiwu Liu and Huguette Albrecht and Arutselvan Natarajan and Julie Sutcliffe and Carolyn Anderson and Li Peng and Riccardo Ferdani and Simon R. Cherry and Kit Sang Lam},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  year={2009},
  volume={50 4},
  pages={625-34}
}
UNLABELLED N-[[4-[[[(2-ethylphenyl)amino]carbonyl]amino]phenyl]acetyl]-N(epsilon)-6-[(2E)-1-oxo-3-(3-pyridinyl-2-propenyl)]-l-lysyl-l-2-aminohexanedioyl-(1-amino-1-cyclohexane)carboxamide (LLP2A) is a high-affinity, high-specificity peptidomimetic ligand (inhibitory concentration of 50% = 2 pM) that binds the activated alpha4beta1 integrin found on a variety of malignant lymphoid cell lines. To better determine whether this ligand holds promise for imaging and therapy in lymphoid malignancies… CONTINUE READING
12 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…